with as quarter that growing opens image-guided Thank Avinger events us. significant pathway business, will March, the peripheral with In partnership first for Greater Matt. two in for Zylox-Tonbridge, progress which we exciting company and had a thank joining you for strategic new the Along opportunities our afternoon, market. all China our in move a the Good vast and of you, we forward. devices to continued we announced our provide introduction
exciting During quarter, coronary development verification filing in we the the first our the FDA validation this also proprietary product, for made CTO-crossing we our as studies progress Phase first device of an year. for and III prepare submission IDE later with initiating
a vascular a strategic Since Standard. equity has in is the facility $XX XXXXX:XXXX new million in fully into the Quality Starting and and partnership. preferred in of an Hangzhou, are the agreement, state-of-the-art stock the manufacturing China markets. interventional with to X products company International markets purchase certified the headquarters They our maintain Zylox Zylox-Tonbridge of in peripheral ISO in Avinger invest neurovascular a XX and tranches. and will launched financing terms at and their common in Under up to new XXXX, leader medical China China. developed Zylox device integrated Greater founding their through
over investment and first of manufacturer tranche as funded million products million quarters. $X.X million $X.X revenue tranche, achieving the Avinger's upon in consecutive second funded with milestones X Zylox achieving a successfully equity will The U.S. was registering including aggregate a in $XX FDA March, key be Avinger
to image-guided Taiwan. and including Kong, proprietary Mainland manufacture license technology distribute agreement, exclusive devices Avinger's China Under and transfer the terms rights China, Macau and the region, Greater in Zylox has Hong of a
in their as supporting they are the of registration prepare Zylox China. regulatory process for Avinger in We products
products Zylox China until regulatory has for and own in time be manufacturing the royalty authorization of products territory Avinger. initial as their the sell to such launch Following Zylox Avinger Avinger gained for Avinger manufacturing will bearing for regulatory Zylox clearance, their products established will to product markets. capability Sales
the well sales distribute of than U.S. product gross and source believe cost-plus network, related their to of overhead sold, in XXX an have and the Greater manufacturing a registered extensive the opportunity extremely a is could been basis. Zylox from in Zylox FDA, on more will distribution products to has reduce Once We successfully as cost employees capability and Avinger expense and to and Avinger's we China with facility reduced goods option margin products the future. manufacturer established region. qualified marketing Zylox With in Avinger this provide finished improve the for
the providing collaboration a our and about strategic great we're over vast start, pathway benefits and margin with structure off brings and cost Zylox to a Avinger, improve creating relationship new opportunity our to the to this excited to strengthening gross Our is sheet, time. balance markets
to turning development our Now coronary program.
provides and very large image-guided device, an which excited system are the redefine are to we progress of the coronary We CTO-crossing the upon in development underserved believe our about making our a proven opportunity platform, first technology market. we based
coronary development extensive an and physicians, and OCT animal with Following cadaveric process expert multiple rounds and KOL intravascular and CTO-crossing in studies imaging. of heart studies design
We with we the have Phase allow of a year for advanced quarter position the in required validation and the successful Phase approval. have following clinical IDE being this in Pending completed third FDA verification file to development product II program anticipate the initiation to of study III submission completion to of testing, an our a design development process. and selection in
more coronary simplified leveraging for and in By complex, have physicians occlusions exposure radiation a failure for the technology, chronic contrast CTO predictable we crossing high total with need can less we Crossing rates. be and solution provide proprietary usage. time-consuming image-guided media believe can coronary our superior, arteries and the with
combines steer-ability success to approach, times OCT system low and X-French design improve significantly with control real-time expect profile procedure nanogrid features a crossing coronary catheter that reduce Our facilitate and which we rates. guidance precise to
our reliance prior balloons placement, is peripheral coronary measurement think optimal capability incorporates to stents solution critical Like contrast pose size can specialty which physicians to recanalization or this also our usage catheters, various properly support X-ray on for reentry health our wires, device precise radiation a outcomes. We risks. while devices help which the less of and limiting dye, catheters, exposure devices, can with accomplish and iodine-containing
confident believe image practice. vessel control hospital are proposition, value crossing certain and accessory significant contrast in We coronary cost safety present clinical the the robust and savings time, would our usage We combination for guidance need profile system. compelling within during support the devices will precise result economic CTO-crossing our of onboard highly a for device a will reducing media
upon think for sense this excited we coronary codes IDE imaging product perspective, existing this to we're and a from also clinical would makes clearance. would In not later access and CTO-crossing, as advance system for our FDA both existing We provide it further filing great updates reimbursement OCT access diagnostic codes revolutionary this year. immediately high-value addition, only to business coronary
with During the peripheral make to business. also first progress our quarter, we continued
onboarding and through and have completed their advance proficiency are and our sales new clinical representatives accounts they sales clinical new the specialists sales with process. users Our as and devices their gaining pipelines build
as new growth new of to for device in commercial Pantheris prepare CTO year. ST crossing increase valuable the device clinical expansion with vessel our later we continues business. Tigereye experience CTO And gain and half Our this support continue we LV large to atherectomy launched penetration the our last market of second year,
financial Accounting call Financial the to and Officer this Nabeel over Subainati, I'll to our At Officer, point, Principal turn to and Nabeel? us Q&A. the for I'd then through results, take like return
